What do you think of Sinopharm Shangyao s 96 national procurement and distribution?

It should be to prevent Sinopharm from being purchased by other pharmaceutical companies privately, resulting in the hoarding of Sinopharm and the country's strategic materials being hoarded by private individuals.

I think a specific distribution company, this will be easier to manage, but also better supervision, if the distribution is dispersed, the management is not in place, the drug delivery is not timely, this is also a big problem.

It's all about profits.

This can make people feel very reassured and make people feel that the state cares about the people.

There's nothing to brag about, it's all state-owned, and everyone does the same.

In this round of competition for the right to purchase and distribute the country, it won overwhelmingly and advantageously, which also means that the pattern of the circulation field has undergone great changes, and the concentration of the industry is increasing rapidly.

It means that at present, domestic drug dispensing enterprises have presented a new situation, and they are no longer scattered small groups.

This means that the vast majority of drugs in the domestic pharmaceutical market rely on Sinopharm to complete.

Because the two companies of Sinopharm and Shanghai Pharmaceutical have developed very rapidly in recent years, they have spread all over the country's dispensing network.

Because the production line of Sinopharm is not only complete, but also of high quality, and the drugs are competitive.

In order to better speed up the circulation of traditional medicine and reduce the distribution cost of traditional medicine, so that the entire industry can evolve and upgrade faster.

Recently, the results of the third batch of national centralized drug procurement were announced, and the Shanghai Pharmaceutical Recruitment Institute immediately announced the list of distribution companies in Shanghai, from the list, in addition to Beijing Jingfeng Pharmaceutical metformin and Hangzhou Kangenbei's finasteride tablets were distributed by Shanghai Jointown and Shanghai Merro PharmaceuticalSinopharm and Shanghai Medicine have the right to distribute all the remaining drugs, about 96% of the total.

According to the calculation of the reported volume, Sinopharm, Shanghai Medicine, Jointown and Metro will undertake about 70 million yuan, 100 million yuan, 2.36 million yuan and 5.7 million yuan of drug distribution tasks respectively.

The mode of pharmaceutical distribution will change from decentralized to centralized, because there were many small pharmacies before, but now they are basically monopolized by these two companies.

This shows that the degree of monopoly of leading enterprises is deepening, the concentration of the industry is increasing rapidly, and some national procurement and distribution have become more and more concentrated in the hands of a few large enterprises.

Sinopharm Shangyao covers 96% of the national procurement and distribution, and there have been huge changes in the field of China's pharmaceutical circulation, although Sinopharm still covers most of the distribution, but there is still a part of the distribution right in the hands of individual enterprises, which is already a good progress!

According to the results of the third batch of national procurement to be selected, in addition to Beijing Jingfeng Pharmaceutical's metformin and Hangzhou Kangenbei's finasteride tablets are distributed by Shanghai Jointown and Shanghai Merro Pharmaceutical respectively, Sinopharm and Shanghai Pharmaceutical account for the remaining 96% of the national procurement and distribution, which also means that the concentration of China's pharmaceutical circulation industry is rapidly improving, and the pattern of domestic circulation is also changing. The third batch of 55 varieties of national procurement has shrunk by 86% of the market size, most of which will be paid from the intermediate links, which has higher requirements for the business coverage area and core competitiveness of pharmaceutical circulation service providers.

In recent years, with the promulgation of the national "two-invoice system", the crackdown on tax-related violations has been strengthened, many small-scale pharmaceutical circulation enterprises and wholesale and retail enterprises have been eliminated, and more pharmaceutical companies are mergers and acquisitions. In recent years, our country is also looking at foreign countries, the concentration of the top three pharmaceutical distribution enterprises in the United States is as high as 96%, while the top four enterprises in China are only about 39%, and the number of pharmaceutical wholesale enterprises and retail enterprises in the past is large, and most of them are scale, low concentration.

The pharmaceutical circulation industry is an important industry related to people's health and life safety, the state also attaches great importance to this, from the previous "two-invoice system", now it is in some cities to pilot the "one-invoice system", by the production enterprises to choose the distribution enterprises, and directly encourage hospitals and drug manufacturers to directly settle drug payments, has also been in Fujian, Zhejiang, Hubei, Shanxi, Shaanxi, Tianjin, Shandong and other 11 provinces and cities pilot.

In general, with the policy of "two-invoice system" and "one-invoice system", pharmaceutical business leaders will also win more distribution rights of pharmaceutical varieties, and the concentration of pharmaceutical circulation market will also increase rapidly. These traditional pharmaceutical circulation industries will also face greater market challenges in the future, and JD.com, SF Express, and postal services have also joined this competition.